Literature DB >> 20453041

Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Andreas Heinz1, Florian Schlagenhauf.   

Abstract

A dysregulation of the mesolimbic dopamine system in schizophrenia patients may lead to aberrant attribution of incentive salience and contribute to the emergence of psychopathological symptoms like delusions. The dopaminergic signal has been conceptualized to represent a prediction error that indicates the difference between received and predicted reward. The incentive salience hypothesis states that dopamine mediates the attribution of "incentive salience" to conditioned cues that predict reward. This hypothesis was initially applied in the context of drug addiction and then transferred to schizophrenic psychosis. It was hypothesized that increased firing (chaotic or stress associated) of dopaminergic neurons in the striatum of schizophrenia patients attributes incentive salience to otherwise irrelevant stimuli. Here, we review recent neuroimaging studies directly addressing this hypothesis. They suggest that neuronal functions associated with dopaminergic signaling, such as the attribution of salience to reward-predicting stimuli and the computation of prediction errors, are indeed altered in schizophrenia patients and that this impairment appears to contribute to delusion formation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20453041      PMCID: PMC2879696          DOI: 10.1093/schbul/sbq031

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  71 in total

Review 1.  The current status of the dopamine hypothesis of schizophrenia.

Authors:  A Carlsson
Journal:  Neuropsychopharmacology       Date:  1988-09       Impact factor: 7.853

2.  Schizophrenic psychology, associative learning and the role of forebrain dopamine.

Authors:  R Miller
Journal:  Med Hypotheses       Date:  1976 Sep-Oct       Impact factor: 1.538

3.  No D2 receptor increase in PET study of schizophrenia.

Authors:  L Farde; F A Wiesel; H Hall; C Halldin; S Stone-Elander; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1987-07

4.  Delusional thinking and perceptual disorder.

Authors:  B A Maher
Journal:  J Individ Psychol       Date:  1974-05

Review 5.  The neural basis of drug craving: an incentive-sensitization theory of addiction.

Authors:  T E Robinson; K C Berridge
Journal:  Brain Res Brain Res Rev       Date:  1993 Sep-Dec

6.  Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex.

Authors:  E D Abercrombie; K A Keefe; D S DiFrischia; M J Zigmond
Journal:  J Neurochem       Date:  1989-05       Impact factor: 5.372

7.  Amphetamine modulates human incentive processing.

Authors:  Brian Knutson; James M Bjork; Grace W Fong; Daniel Hommer; Venkata S Mattay; Daniel R Weinberger
Journal:  Neuron       Date:  2004-07-22       Impact factor: 17.173

8.  Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task.

Authors:  W Schultz; P Apicella; T Ljungberg
Journal:  J Neurosci       Date:  1993-03       Impact factor: 6.167

Review 9.  Limbic-striatal interactions in reward-related processes.

Authors:  T W Robbins; M Cador; J R Taylor; B J Everitt
Journal:  Neurosci Biobehav Rev       Date:  1989 Summer-Fall       Impact factor: 8.989

10.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.

Authors:  D F Wong; H N Wagner; L E Tune; R F Dannals; G D Pearlson; J M Links; C A Tamminga; E P Broussolle; H T Ravert; A A Wilson; J K Toung; J Malat; J A Williams; L A O'Tuama; S H Snyder; M J Kuhar; A Gjedde
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

View more
  144 in total

1.  Fronto-striatal dysfunction during reward processing in unaffected siblings of schizophrenia patients.

Authors:  Max de Leeuw; René S Kahn; Matthijs Vink
Journal:  Schizophr Bull       Date:  2014-11-02       Impact factor: 9.306

Review 2.  Brain-derived neurotrophic factor and neuropsychiatric disorders.

Authors:  Anita E Autry; Lisa M Monteggia
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

3.  Successful learning in schizophrenia, functional neuroimaging studies, and theoretical considerations.

Authors:  Henry H Holcomb; Graham K Murray
Journal:  Schizophr Bull       Date:  2010-04-19       Impact factor: 9.306

4.  Metabotropic glutamate receptor blockade in nucleus accumbens shell shifts affective valence towards fear and disgust.

Authors:  Jocelyn M Richard; Kent C Berridge
Journal:  Eur J Neurosci       Date:  2010-12-29       Impact factor: 3.386

Review 5.  Motivational Deficits in Schizophrenia and the Representation of Expected Value.

Authors:  James A Waltz; James M Gold
Journal:  Curr Top Behav Neurosci       Date:  2016

6.  Effect of methylphenidate on mismatched visual information processing in young healthy volunteers: an event-related potential study.

Authors:  Chunyu Han; Yuping Wang; Mian Shi; Wei Mao; Wei Sun
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 7.  Functional connectivity as a means to delineate differences between treatment-resistant and treatment-responsive schizophrenia.

Authors:  Sara Paul; Nathan Sharfman
Journal:  J Neurophysiol       Date:  2016-01-13       Impact factor: 2.714

8.  [The German research network for mental disorders].

Authors:  M Bauer; T Banaschewski; A Heinz; I Kamp-Becker; A Meyer-Lindenberg; F Padberg; M A Rapp; R Rupprecht; F Schneider; T G Schulze; H-U Wittchen
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

Review 9.  Neurobiological Models of Self-Disorders in Early Schizophrenia.

Authors:  A Mishara; I Bonoldi; P Allen; G Rutigliano; J Perez; P Fusar-Poli; P McGuire
Journal:  Schizophr Bull       Date:  2015-09-18       Impact factor: 9.306

Review 10.  Pain and analgesia: the value of salience circuits.

Authors:  David Borsook; Robert Edwards; Igor Elman; Lino Becerra; Jon Levine
Journal:  Prog Neurobiol       Date:  2013-03-07       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.